drug

Ashwagandha

MeSH C030693
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
DIETARY_SUPPLEMENT
Pre-approval / investigational in the US
Developed by Hasanuddin University
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
DIETARY_SUPPLEMENT

Indications

Trials

2
Effect of Ashwagandha as Adjunct Therapy on BDNF and Cognitive Function in Schizophrenia Patients
NCT07541157—Completed
Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone
NCT07575516Phase 2Completed

KOLs & investigators

2
Masnaeni Awaliah, MD
Rina Nurul Qalbi, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Hasanuddin University
company
trial
Effect of Ashwagandha as Adjunct Therapy on BDNF and Cognitive Function in Schizophrenia Patients
NA
trial
Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone
PHASE2
trial
indication
Schizophrenia
indication
Inflammation
indication
Neuroinflammatory Diseases
indication
Neuroinflammation
indication
KOL
Masnaeni Awaliah, MD
KOL score —
person
Rina Nurul Qalbi, MD
KOL score —
person